13F Holdings
中文EN

NEUP Neuphoria Therapeutics Inc.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1191070 · Fiscal year ends 06/30

Financial factors as of 2026-09-30 (2027Q1), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY47.5%
TTM EPS YoY127.1%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE-27.6%
ROA-18.3%
ROIC (approx.)-568.0%
Asset turnover—

Leverage & solvency

Liabilities / assets13.4%
Debt / equity0.00x
Current ratio18.05x
Interest coverage—

Cash quality & payout

Operating cash flow / net income1.95x
Accruals ratio17.3%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20262026-06-30 · USDFY20252025-06-30 · USDFY20242024-06-30 · USDFY20232023-06-30 · USDFY20222022-06-30 · AUD
Income statement
Revenue$1.17M$15.65M—22,047AUD263,634
R&D expense—$9.01M$9.42M$13.07M16.00M
SG&A expense$7.44M$7.77M$8.47M$8.91M—
Operating income-$16.45M-$1.13M-$17.89M-$21.98M—
Interest expense———29,230AUD44,165
Pretax income-$13.59M-$837,998-$15.58M-$21.52M-21.95M
Income tax-$139,173-$468,366-$87,320-$139,174-191,808
Net income-$13.45M-$369,632-$15.49M-$21.38M913,373
EBITDA-$15.79M-$466,201-$17.23M-$21.32M—
EPS (basic)-3.06-0.23-18.62-0.02-0.02
EPS (diluted)-3.06-0.23-18.62-0.02-0.02
Weighted avg. shares (diluted)4.40M1.62M832,2251.47B1.35B
Balance sheet
Cash & equivalents$19.87M$14.29M$12.69M$12.18M33.56M
Receivables$813,431$11,948$126,884$426,08764,360
Current assets$21.07M$15.04M$13.19M$13.33M41.81M
PP&E, net—$2,771$1,994$2,5225,172
Goodwill$3.50M$8.64M$8.69M$8.69M12.87M
Intangibles$4.14M$4.80M$5.47M$6.13M9.84M
Total assets$28.71M$28.59M$27.65M$28.56M65.31M
Current liabilities$756,581$4.22M$3.83M$2.74M3.36M
Total liabilities$4.11M$9.59M$10.16M$6.55M8.40M
Shareholders' equity$24.60M$19.00M$24.60M$22.01M$39.23MUSD
Shares outstanding5.41M1.98M1.10M1.47B—
Cash flow statement
Operating cash flow-$12.35M$77,229-$14.68M-$14.64M-21.76M
Capital expenditure————1,544
Free cash flow————-21.76M
Investing cash flow———479,528AUD621,703
Financing cash flow$17.92M$1.53M$15.11M$3.86M27.00M
Depreciation & amortization$662,955$662,890$662,991$663,1921.11M
Stock-based compensation$351,600$163,772$814,808$1.35M2.83M

Free plan shows the latest 5 periods; Pro shows all 7 🔒

· This company uses different currencies across periods or line items (e.g. USD convenience translations in annual reports). Each column header shows its currency and cells in a different currency are marked; do not compare figures across currencies. Charts use only periods in the latest period's currency.

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.